Hepatorenal Syndrome Market Report 2026

The hepatorenal syndrome market size has grown strongly in recent years. It will grow from $1.37 billion in 2025 to $1.46 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing prevalence of chronic liver disease, rising incidence of cirrhosis-related complications, expansion of intensive care unit infrastructure, growing clinical awareness of HRS diagnosis, availability of vasoconstrictor-based therapies.

The hepatorenal syndrome market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to increasing liver transplant procedures, rising focus on early-stage HRS detection, expansion of advanced renal support therapies, growing adoption of precision medicine approaches, increasing investment in hepatology-focused clinical research. Major trends in the forecast period include increasing adoption of targeted vasoconstrictor therapies, growing use of early diagnostic biomarkers, rising focus on multidisciplinary critical care management, expansion of albumin-based combination treatments, enhanced monitoring of renal function in liver disease patients.

The rising prevalence of liver diseases is expected to drive the growth of the hepatorenal syndrome market in the coming years. Liver diseases, including hepatitis, cirrhosis, fatty liver, liver cancer, genetic disorders, and autoimmune conditions, impair liver function. Factors such as obesity, diabetes, alcohol consumption, viral infections, poor diet, and toxin exposure contribute to the increasing prevalence of these conditions. The higher incidence of liver diseases, particularly cirrhosis and acute liver failure, elevates the risk of hepatorenal syndrome (HRS) by causing severe hemodynamic and kidney dysfunction due to progressive liver impairment. For example, according to the Office for Health Improvement & Disparities (OHID), a UK government department, hospital admissions for liver disease in the UK rose to 155.2 per 100,000 population in 2023, up from 150.6 per 100,000 in 2022. Consequently, the rising prevalence of liver diseases is driving the hepatorenal syndrome market.

Increasing investments in research and development (R&D) are also expected to propel the growth of the hepatorenal syndrome market. R&D investments refer to funds allocated for innovation, product improvement, and the development of new technologies. Growth in R&D spending is driven by technological advancements, competitive pressures, healthcare demands, and the need for innovation. In hepatorenal syndrome, such investments support the development of innovative therapies, diagnostic tools, and treatment approaches, improving patient outcomes and survival rates. For instance, according to the Office for National Statistics, a UK government agency, the UK government’s net R&D spending increased to £17.4 billion ($22.1 billion) in 2023, up from £16.1 billion ($20.45 billion) in 2022, reflecting an 8.2% rise. Therefore, growing R&D investments are contributing to the expansion of the hepatorenal syndrome market.

Key companies in the hepatorenal syndrome market are focusing on innovative therapies and devices to improve patient outcomes by targeting both liver and kidney dysfunction. One such device is the cytopheretic device (Cytosorb), an extracorporeal blood purification therapy designed to reduce systemic inflammation and immune activation in critically ill patients, including those with HRS. For example, in October 2023, SeaStar Medical Holding Corporation, a US-based medical device company, received FDA approval for its Selective Cytopheretic Device (SCD) for treating hepatorenal syndrome. This advanced cell-directed therapy targets hyperinflammation, a key contributor to kidney dysfunction in acute-on-chronic liver failure. By modulating immune responses, SCD supports kidney recovery and may improve eligibility for life-saving liver transplants. Its effectiveness in enhancing solid organ function has been demonstrated in preclinical and clinical studies across conditions such as sepsis, acute kidney injury (AKI), and cardiorenal syndrome.

Major companies operating in the hepatorenal syndrome market are Eli Lilly and Company, Baxter International Inc., Mallinckrodt Pharmaceuticals, Ferring Pharmaceuticals Ltd, La Jolla Pharmaceutical Company, Teva Pharmaceutical Industries Ltd, Cumberland Pharmaceuticals Inc., Innoviva Specialty Therapeutics Inc, BioVie Inc., SeaStar Medical, Otsuka Pharmaceutical Co. Ltd, Pfizer Inc., AbbVie Inc., Bristol Myers Squibb, Novartis AG, Sanofi, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Bayer AG, AstraZeneca.

North America was the largest region in the hepatorenal syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatorenal syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatorenal syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hepatorenal syndrome market by increasing costs of imported active pharmaceutical ingredients, biologics, diagnostic reagents, infusion devices, and dialysis equipment used in hospital-based treatment settings. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported critical care drugs and renal support systems, while Asia-Pacific faces pricing pressure on pharmaceutical imports. These tariffs are contributing to higher treatment costs and procurement challenges. However, they are also encouraging local drug manufacturing, regional sourcing of medical supplies, and increased investment in domestic pharmaceutical production capabilities.

The hepatorenal syndrome market research report is one of a series of new reports that provides hepatorenal syndrome market statistics, including hepatorenal syndrome industry global market size, regional shares, competitors with a hepatorenal syndrome market share, detailed hepatorenal syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the hepatorenal syndrome industry. This hepatorenal syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatorenal Syndrome (HRS) is a serious complication of advanced liver disease, characterized by functional kidney failure caused by reduced renal blood flow without structural kidney damage. It results from splanchnic vasodilation, which triggers renal vasoconstriction and a decrease in glomerular filtration.

The main types of hepatorenal syndrome include type 1 HRS, type 2 HRS, and other variants. Type 1 HRS is a rapidly progressing form of kidney failure in patients with advanced liver disease, marked by a sharp decline in kidney function over days to weeks. Treatment options include liver transplantation, terlipressin infusion, albumin infusion, hemodialysis, vasoconstrictors, and antibiotic therapy. Diagnosis involves tests such as complete blood count, liver function tests, urinalysis, and urine electrolytes, among others. Treatments and related products are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Primary end-users include hospitals, specialty clinics, homecare settings, and other healthcare providers.

The hepatorenal syndrome market consists of revenues earned by entities by providing services such as medical management services, dialysis services, and liver transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatorenal syndrome market also includes sales of angiotensin, dialysis products, and continuous renal replacement therapy (CRRT) machines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.